МИРАБЕГРОН. СОСТОИТСЯ ЛИ РЕВОЛЮЦИЯ В ФАРМАКОТЕРАПИИ ГИПЕРАКТИВНОГО МОЧЕВОГО ПУЗЫРЯ?


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Данная статья представляет собой обзор современного состояния проблемы эффективной фармакотерапии гиперактивного мочевого пузыря (ГМП). В обзоре представлена как стандартная фармакотерапия, так и новый этап лечения ГМП - инновационный препарат Мирабегрон. В ходе международных и отечественных исследований подтверждены высокая и преимущественная по многим показателям эффективность мирабегрона, а также благоприятный профиль безопасности. В ходе собственного исследования, проведенного в НИИ урологии, доказано отсутствие отрицательного влияния препарата на качество фазы опорожнения мочевого пузыря, что подтверждает уродинамическую безопасность. С учетом доказанной в рандомизированных сравнительных исследованиях эффективности мирабегрона в отношении всех симптомов ГМП мирабегрон имеет огромный потенциал и способен совершить революцию в фармакотерапии ГМП.

Полный текст

Доступ закрыт

Об авторах

В. В. Ромих

«НИИ урологии и интервенционной радиологии им. Н. А. Лопаткина» - филиал НМИРЦ Минздрава России

Email: vromikh@yandex.ru
руководитель отдела нейроурологии и уродинамики

Л. Ю. Борисенко

«НИИ урологии и интервенционной радиологии им. Н. А. Лопаткина» - филиал НМИРЦ Минздрава России

А. В. Захарченко

«НИИ урологии и интервенционной радиологии им. Н. А. Лопаткина» - филиал НМИРЦ Минздрава России

Список литературы

  1. Kondo A., Kato K., Takita T., Otani T. Holding postures characteristic of unstable bladder. J Urol. 1985;134(4) :702-704.
  2. Van Gool J.D., de Jonge G.A. Urge syndrome and urge incontinence. Arch Dis Child. 1989;64 (11):1629-1634.
  3. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. Standardisation Sub-committee of the International Continence Society The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178.
  4. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl. 1):2-6.
  5. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760- 766.
  6. Stewart W.F., Van Rooyen J.B., Cundiff G.W., Abrams P., Herzog A.R., Corey R., Hunt T.L., Wein A.J. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-36.
  7. Morrison J., Steers W.D., Brading A.F. Neurophysiology and neuropharmacology. Abrams P., Cardozo L., Khoury, Wein A., eds. Incontinence. 2nd ed. Plymouth, England: Health Publications; 2002: 86-163.
  8. Yoshimura N., Chancellor M.B. Current and future pharmacological treatment for overactive bladder. J Urol. 2002;168(5):1897-1913.
  9. Igawa Y., Aizawa N., Homma Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol. 2010;51(12):811-818.
  10. Burgio K.L. Influence of behavior modification on overactive bladder. Urology. 2002;60(5 Suppl. 1):72-76.
  11. [Guideline] American Urological Association. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guidelines. March 26, 2013.
  12. Khasriya R., Khan S., Lunawat R., Bishara S., Bignall J., Malone-Lee M., Ishii H., O'Connor D., Kelsey M., Malone-Lee J. The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with low urinary tract symptoms without acute frequency and dysuria. J Urol. 2010;183:1843-1847.
  13. Foxman В., Valdez R.B., Brock R.H. Childhood enuresis: prevalence, perceived impact and presented treatments. Pediatrics 1986;77:482-487.
  14. Пугачев А.Г., Ромих В.В., Алферов С.М. Клинические особенности функциональных нарушений мочеиспускания в детском возрасте. Лечащий Врач. 2004;9:35-38.
  15. Вишневский Е.Л., Пугачев А.Г. Недержание мочи у детей. Пленум правления Российского общества урологов, Ярославль: Материалы. М., 2001. С. 179-189.
  16. Steers W.D., Herschorn S., Kreder K.J., Moore K., Strohbehn K., Yalcin I., Bump R.C. Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007 ; 100(2):337-345.
  17. Vella M., Duckett J., Basu M. Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(7):961-964.
  18. Guidelines on Urinary incontinence. European Association of Urology 2015.
  19. Mattiasson A., Abrams P., van Kerrebroeck P., Walters S., Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 2002;89:855-862.
  20. Lose G., Lalos O., Freeman R.M., van Kerrebroeck P. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol. 2003;189:1106-1113.
  21. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn. 2004;23:302-305.
  22. Robinson D., Cardozo L., Akeson M., Hvistendahl G., Riis A., Norgaard J.P. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int. 2004;93(7):996-1000.
  23. Young Kook Han, Won Ki Lee, Seong Ho Lee, Dae Yul Yang, Hayoung Kim. Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder. Korean J Urol. 2011;52:396-400.
  24. Cardoso L. Systematic review of overactive bladder therapy in females. Can Urol Assoc J. 2011;5(5 Suppl. 2):139-S142.
  25. Tseng L.H., Wang A.C., Chang Y.L., Soong Y.K., Lloyd L.K., Ko Y.J. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28:47-51.
  26. Serati M., Salvatore S., Uccella S., Cardozo L., Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol. 2009;55:713-719.
  27. Robinson D., Cardoso L. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007 ; 100(4):840-845.
  28. D'Souza A., Smith M., Miller L., Doyle J., Ariely R Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14:291-301.
  29. Igawa Y., Aizawa N., Homma Y. Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol. 2010;51:811-818.
  30. Takeda H., Yamazaki Y., Akahane M., Igawa Y., Ajisawa Y., Nishizawa O. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp Ther. 2000;293:939-945.
  31. Otsuka A., Shinbo H., Matsumoto R., Kurita Y., Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:473-481.
  32. Lindholm, P., Lose G. Terbutaline (Bricanyl) in the treatment of female urge incontinence. Urol Int. 1986;41:158-160.
  33. Gruneberger A. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride. Br J Obstetr Gynaecol. 1984;91:275-278.
  34. Kaidoh K., Igawa Y., Takeda H., Yamazaki Y., Akahane S., Miyata H., Ajisawa Y., Nishizawa O., Andersson K.E. Effects of selective β2 and β3-adrenoceptor agonists in detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol. 2002;168:1247-1252.
  35. Takasu T., Ukai M., Sato S., Matsui T., Nagase I., Maruyama T., Sasamata M., Miyata K., Uchida H., Yamaguchi O. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321: 642-647.
  36. Yamaguchi O., Chapple C. b3-Adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26:752-756.
  37. Kanai A., Wyndaele J.J., Andersson K.E., Fry C., Ikeda Y., Zabbarova I., De Wachter S. Researching bladder afferents determining the effects of b3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn. 2011;30:684-691.
  38. FDA (2012) Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron, 5 April 2012. Division of Reproductive and Urologic Products, Office of New Drugs Center for Drug Evaluation and Research of Food and Drug Administration. Available at: http://www. fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM298284.pdf (accessed 19 July 2012).
  39. Takusagawa S., van Lier J.J., Suzuki K., Nagata M., Meijer J., Krauwinkel W., Schaddelee M., Sekiguchi M., Miyashita A., Iwatsubo T., van Gelderen M., Usui T. Absorption, metabolism and excretion of [14C] mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40:815-824.
  40. van Gelderen E., Li Q., Meijer J., Schaddelee M., Takusagawa S., Sugawarw T. An explanatory comparison of the single dose pharmacokinetics of the beta3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther. 2009;85(Suppl. 1): abstr. PIII-65.
  41. Chapple C., Yamaguchi O., Ridder A., Liehne J., Carl S., Mattiasson A. et al. Clinical proof of concept study (Blossom) shows novel b3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol. 2008; 239(Suppl. 7):abstr. 674.
  42. Chapple C., Wyndaele J., Van Kerrebroeck P., Radziszewski P., Dvorak V., Boerrigter P. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol. 2010;(Suppl 9.):249.
  43. Khullar V., Cambronero J., Angulo J., Wooning M., Blauwet M., Dorrepaal C. et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): post-hoc analysis of a prospective, randomised European - Australian phase III trial. Eur Urol. 2012;(Suppl. 11):e684-e684a.
  44. Chapple C., Kaplan S., Mitcheson H., Klecka J., Cummings J., Drogendijk T. et al. Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB). Eur Urol. 2012;(Suppl. 11):e683-e683a.
  45. Nitti V.W., Rosenberg S., Mitcheson D.H., He W., Fakhoury A., Martin N.E. Urodynamics and safety of the β3-adrenoceptor agonist mirebegron, in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4) :1320-1327.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2015